<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133076</url>
  </required_header>
  <id_info>
    <org_study_id>PEC19156</org_study_id>
    <nct_id>NCT05133076</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications</brief_title>
  <acronym>OIC1</acronym>
  <official_title>A Randomized Placebo-controlled Study to Assess Safety and Preliminary Efficacy of BGP345A in Patients With Constipation Due to the Use of Opioid-based Medications for the Management of Chronic Non Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGaia Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioFortis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioGaia Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and preliminary efficacy of BGP345A in patients&#xD;
      with constipation due to the use of opioid-based medications for the management of chronic&#xD;
      non cancer pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the average weekly number of Spontaneous Bowel Movements (SBMs) (expressed in number of stools/week)</measure>
    <time_frame>Over the 4 week treatment period</time_frame>
    <description>A SBM (Spontaneous Bowel Movement) is defined as a bowel movement without the use of laxatives in the previous 24 hours as recorded in the daily diary (Webster LR et al, 2017).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders over the 4-weeks of treatment period defined by subjects reporting an average weekly number of SBMs ≥ 3 and an increase of the average weekly number of SBM ≥1 from baseline</measure>
    <time_frame>Average over the last two weeks of treatment</time_frame>
    <description>SBM responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average weekly number of BMs (Bowel Movements)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>BM (Bowel Movements) expressed in number of stools/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average weekly number of CSBMs (Complete Spontaneous Bowel Movement)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>CSBMs (Complete Spontaneous Bowel Movement) expressed in number of stools/week is defined by as a bowel movement without the use of laxatives in the previous 24 hours as recorded in the daily diary and the feeling of complete emptying after bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average weekly number of SBMs</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>SBMs expressed in number of stools/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average weekly number of SBMs with no straining (straining score 1)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>SBMs expressed in number of stools/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first SBM and CSBM after the last recorded stool before the randomisation</measure>
    <time_frame>Over 4 week treatment period</time_frame>
    <description>Expressed in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of days with presence of SBMs</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>SBMs expressed in days/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of days with presence of CSBMs</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>CSBMs expressed in days/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average weekly number of SBMs rated 3 or 4 on the BSS (Bristol Stool Scale)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>Expressed in stools/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of stool consistency assessed by the BSS (Bristol Stool Scale)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>Expressed in arbitrary units/stool from 1-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the overall BFI (Bowel Function Index) score</measure>
    <time_frame>Over 4 week treatment period</time_frame>
    <description>Expressed in arbitrary units, range 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average daily abdominal bloating score</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>Expressed in arbitrary units/day (this score will be assessed daily for the past 24hours and could range from 0 to 4, where 0 = absent or no bloating, 1 = mild, 2 = moderate, 3= severe, and 4 =very severe bloating)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average daily abdominal discomfort score</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>Expressed in arbitrary units/day (this score will be assessed daily for the past 24hours and could range from 0 to 4, where 0 = no abdominal discomfort, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average daily pain at defecation assessed by the Visual Analogic Scale for pain at defecation (VAS)</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>Expressed in arbitrary units/day with stool, range 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the weekly frequency of rescue laxative use assessed by the daily diary</measure>
    <time_frame>Over 4 week treatment period; during each week of the treatment period; and up to 8 weeks at study completion.</time_frame>
    <description>expressed in average of days/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rescue laxative use assessed by the daily diary.</measure>
    <time_frame>Over the 4 week treatment period</time_frame>
    <description>Expressed in number of laxative uses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health state measuring vital parameters assessed - Body weight</measure>
    <time_frame>Through study completion, 10 weeks</time_frame>
    <description>Body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health state measuring vital parameters assessed- Diastolic Blood Pressure</measure>
    <time_frame>Through study completion, 10 weeks</time_frame>
    <description>Diastolic Blood Pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health state measuring vital parameters assessed- Systolic Blood Pressure</measure>
    <time_frame>Through study completion, 10 weeks</time_frame>
    <description>Systolic Blood Pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health state measuring vital parameters assessed- Vital signs</measure>
    <time_frame>Through study completion, 10 weeks</time_frame>
    <description>Vital signs (BPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of adverse events (AE), serious adverse events (SAE), Treatment-Emergent Adverse events (TEAE), Serious treatment-emergent adverse events (STEAE)</measure>
    <time_frame>Through study completion, 10 weeks</time_frame>
    <description>Frequency and nature of events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Opioid-Induced Constipation</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus gasseri DSM 27123</intervention_name>
    <description>Active and placebo capsules for oral use</description>
    <arm_group_label>Active arm</arm_group_label>
    <other_name>BGP345A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I1. Age over 18 years (limit included),&#xD;
&#xD;
        I2. Diagnosed with OIC according to the adapted ROME IV criteria (Mearin F et al, 2016)&#xD;
        previously used in clinical evaluation of patients with OIC (Webster LR et al, 2017) and&#xD;
        self-reported symptoms assessed by a physician (daily diary check at V1 visit):&#xD;
&#xD;
          -  Fewer than three (&lt;3) spontaneous bowel movements (SBMs) per week. A SBM is defined as&#xD;
             a bowel movement without the use of laxatives in the previous 24 hours as recorded in&#xD;
             the daily diary.&#xD;
&#xD;
          -  And one or more of the following symptoms in at least 25% of bowel movements:&#xD;
             straining, feeling of incomplete evacuation, and/or hard/small stools, defined as&#xD;
             Bristol Stool Scale (BSS) score lower than 3 (&lt;3).&#xD;
&#xD;
        I3. With chronic non-cancer pain since at least three months, including the following&#xD;
        indications but not limited to: back-pain, rheumatisms and post-operative pain,&#xD;
&#xD;
        I4. Patients received opioids for chronic analgesia (intended treatment ≥6 Weeks) for 1&#xD;
        week or more prior to study start and a stable regimen of opioids for 3 or more days before&#xD;
        study entry (V0 visit) and during the whole study ,&#xD;
&#xD;
        I5. Subjects must be willing to discontinue laxative use at screening and only use the&#xD;
        rescue laxatives permitted throughout the study duration,&#xD;
&#xD;
        I6. For women:&#xD;
&#xD;
          -  Non menopausal with the same reliable contraception since at least 2 cycles before the&#xD;
             beginning of the study and agreeing to keep it during the entire duration of the study&#xD;
             (condom with spermicide gel, any oral contraceptive, intrauterine device, subcutaneous&#xD;
             contraceptive implant, vaginal ring, surgical intervention (bilateral tubal ligation&#xD;
             or ovariectomy or hysterectomy), ESSURE system),&#xD;
&#xD;
          -  Menopausal without or with hormone replacement therapy,&#xD;
&#xD;
        I7. Good general and mental health with in the opinion of the investigator: no clinically&#xD;
        significant and relevant abnormalities of medical history or physical examination,&#xD;
&#xD;
        I8. Able and willing to participate to the study by complying with the protocol procedures&#xD;
        as evidenced by his dated and signed informed consent form,&#xD;
&#xD;
        I9. Affiliated with a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E1. Involvement in any investigational drug or device study within 30 days prior to this&#xD;
        study,&#xD;
&#xD;
        E2. Unable to withdraw other OIC treatments (any kind of laxative other than provided in&#xD;
        the study),&#xD;
&#xD;
        E3. History of chronic constipation prior to starting analgesic medication or any potential&#xD;
        non-opioid cause of bowel dysfunction that may be a major contributor to the constipation&#xD;
        upon investigator judgment,&#xD;
&#xD;
        E4. Surgery planned within the whole study period,&#xD;
&#xD;
        E5. Evidence of active medical diseases affecting bowel transit,&#xD;
&#xD;
        E6. Antibiotic treatment intake within the last month prior the study start (V0),&#xD;
&#xD;
        E7. Unwilling to withdraw probiotic supplements, yoghurts without supplemented bacteria are&#xD;
        permitted,&#xD;
&#xD;
        E8. Any history of drug addiction in the past five years,&#xD;
&#xD;
        E9. Pregnant or lactating women or intending to become pregnant,&#xD;
&#xD;
        E10. Unwilling to maintain food habits and current physical activity for the whole study&#xD;
        duration,&#xD;
&#xD;
        E11. With a personal history of anorexia nervosa, bulimia or significant eating disorders&#xD;
        according to the investigator,&#xD;
&#xD;
        E12. Having a lifestyle deemed incompatible with the study according to the investigator&#xD;
        including drug and alcohol abuse,&#xD;
&#xD;
        E13. Taking part in another clinical trial or being in the exclusion period of a previous&#xD;
        clinical trial,&#xD;
&#xD;
        E14. Under legal protection (guardianship, wardship) or deprived from his rights following&#xD;
        administrative or judicial decision,&#xD;
&#xD;
        E15. Presenting a psychological or linguistic incapability to sign the informed consent,&#xD;
&#xD;
        E16. Impossible to contact in case of emergency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra J Lierud</last_name>
    <role>Study Director</role>
    <affiliation>BioGaia Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonia Brinet</last_name>
    <phone>+33 (0)2 40 20 57 99</phone>
    <email>sonia.brinet@biofortis.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Soriot-Thomas, Docteur</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE NANTES (Hôpital Nord Laennec)</name>
      <address>
        <city>Saint- Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Nizard, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Lemaire, Docteur</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Opioid-Induced Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

